Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU2014200003B2 - ALK1 receptor and ligand antagonists and uses thereof - Google Patents
[go: Go Back, main page]

AU2014200003B2 - ALK1 receptor and ligand antagonists and uses thereof - Google Patents

ALK1 receptor and ligand antagonists and uses thereof

Info

Publication number
AU2014200003B2
AU2014200003B2 AU2014200003A AU2014200003A AU2014200003B2 AU 2014200003 B2 AU2014200003 B2 AU 2014200003B2 AU 2014200003 A AU2014200003 A AU 2014200003A AU 2014200003 A AU2014200003 A AU 2014200003A AU 2014200003 B2 AU2014200003 B2 AU 2014200003B2
Authority
AU
Australia
Prior art keywords
ligand
szp
polypeptide
alk1
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014200003A
Other versions
AU2014200003A1 (en
Inventor
Asya Grinberg
John Knopf
Ravindra Kumar
Robert Scott Pearsall
Jasbir Seehra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007317926A external-priority patent/AU2007317926A1/en
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Priority to AU2014200003A priority Critical patent/AU2014200003B2/en
Publication of AU2014200003A1 publication Critical patent/AU2014200003A1/en
Application granted granted Critical
Publication of AU2014200003B2 publication Critical patent/AU2014200003B2/en
Priority to AU2016247166A priority patent/AU2016247166B2/en
Priority to AU2018279010A priority patent/AU2018279010B2/en
Priority to AU2021201063A priority patent/AU2021201063A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

H:\szp\Interwoven\NRPortbl\DCC\SZP\59 186931.DOC-24/12/2013 In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I 5 (ALKl) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
AU2014200003A 2006-11-02 2014-01-02 ALK1 receptor and ligand antagonists and uses thereof Ceased AU2014200003B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2014200003A AU2014200003B2 (en) 2006-11-02 2014-01-02 ALK1 receptor and ligand antagonists and uses thereof
AU2016247166A AU2016247166B2 (en) 2006-11-02 2016-10-20 ALK1 receptor and ligand antagonists and uses thereof
AU2018279010A AU2018279010B2 (en) 2006-11-02 2018-12-14 ALK1 receptor and ligand antagonists and uses thereof
AU2021201063A AU2021201063A1 (en) 2006-11-02 2021-02-18 ALK1 receptor and ligand antagonists and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60/856,592 2006-11-02
AU2007317926A AU2007317926A1 (en) 2006-11-02 2007-11-02 ALK1 receptor and ligand antagonists and uses thereof
AU2014200003A AU2014200003B2 (en) 2006-11-02 2014-01-02 ALK1 receptor and ligand antagonists and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2007317926A Division AU2007317926A1 (en) 2006-11-02 2007-11-02 ALK1 receptor and ligand antagonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016247166A Division AU2016247166B2 (en) 2006-11-02 2016-10-20 ALK1 receptor and ligand antagonists and uses thereof

Publications (2)

Publication Number Publication Date
AU2014200003A1 AU2014200003A1 (en) 2014-01-23
AU2014200003B2 true AU2014200003B2 (en) 2016-07-21

Family

ID=49956550

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014200003A Ceased AU2014200003B2 (en) 2006-11-02 2014-01-02 ALK1 receptor and ligand antagonists and uses thereof

Country Status (1)

Country Link
AU (1) AU2014200003B2 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R&D Systems catalog number 370-AL, retrieved from the website http://www.rndsystems.com/pdf/370-al.pdf, 25 April 2001 *

Also Published As

Publication number Publication date
AU2014200003A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
MX2009004718A (en) Alk1 receptor and ligand antagonists and uses thereof.
WO2009134428A3 (en) Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
WO2009142732A3 (en) Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
MX2010005031A (en) Axl antibodies.
ATE389404T1 (en) KAPPA OPIOID RECEPTOR LIGANDS
MX341014B (en) ANTI-cMET ANTIBODY.
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
YU80903A (en) Antibodies to vla-1
GB0724532D0 (en) Trail variants for treating cancer
IL155875A0 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
ZA200905229B (en) 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
UA95304C2 (en) Use of dll4 antagonists for the prevention of vascular disorders
DK1176963T3 (en) Use of dopamine D3 receptor antagonists in the manufacture of drugs for the treatment of renal dysfunction
Liu et al. Heterodimerization of the kappa opioid receptor and neurotensin receptor 1 contributes to a novel β-arrestin-2–biased pathway
TW200722423A (en) Cyclopentapyridine and tetrahydroquinoline derivatives
ATE458740T1 (en) 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
WO2008057994A3 (en) Pyrrolotriazine kinase inhibitors
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
MX2014009277A (en) Alk1 antagonists and their uses in treating renal cell carcinoma.
MX2010000997A (en) Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e).
MA29339B1 (en) FUSED THIAZOLE DERIVATIVES WITH AFFINITY FOR HISTAMINE H3 RECEPTOR
WO2007024921A3 (en) Combination therapies for inhibiting integrin-extracellular matrix interactions
WO2007022273A3 (en) Vegf-activated fas ligands
WO2011116396A3 (en) Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
AU2014200003B2 (en) ALK1 receptor and ligand antagonists and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired